A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety Tolerability Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients

Go Back to All Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety Tolerability Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients

Brief description of study

This phase I study is designed to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 in healthy participants and initial efficacy in CHB patients. A Safety Review Committee (SRC) will perform ongoing reviews of safety and tolerability based on available study data collected throughout the study. The study will be conducted in four Parts: Part A: SAD in healthy participants (double blinded) Part B: MD in healthy participants (double blinded) Part C: MD in CHB patients (open label) Part D: MD in CHB patients (double blinded; multiple sites)

Clinical Study Identifier: s23-00843

ClinicalTrials.gov Identifier: NCT05717686

Principal Investigator: Ira M. Jacobson.

Other Investigator: Monique Julia Carasso.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies